As a growing number of overweight Americans clamor for Ozempic and Wegovy — drugs touted by celebrities and on TikTok to pare pounds — an even more powerful obesity medicine is poised to upend treatment.
This combination of photos provided by Matthew Barlow shows him in November 2022, left, and April 2023 in California. Barlow, a 48-year-old health technology executive, said he has lost more than 100 pounds since November by using the drug Mounjaro and changing his diet.
Based on the new results, which have not yet been published in full, company officials said they will finalize an application to the U.S. Food and Drug Administration for fast-track approval to sell tirzepatide for chronic weight management. A decision could come later this year. A company spokeswoman would not confirm whether the drug would be marketed for weight loss in the U.S. under a different brand name.
In separate trials, tirzepatide has resulted in greater weight loss than semaglutide, whose users shed about 15% of their body weight over 16 months. A head-to-head trial comparing the two drugs is planned. Rather than relying solely on diet, exercise and willpower to reduce weight, tirzepatide and other new drugs target the digestive and chemical pathways that underlie obesity, suppressing appetite and blunting cravings for food.
“That is a real physical phenomenon,” Aronne said. “There are a number of hormones that respond to reduced calorie intake.” There are other downsides: Versions of semaglutide have been on the market for several years, but the long-term effects of taking drugs that override human metabolism are not yet clear. Early evidence suggests that when people stop taking the medications, they gain the weight back.
Singapore Latest News, Singapore Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Powerful new obesity drug poised to upend weight loss careAs a growing number of overweight Americans clamor for Ozempic and Wegovy — drugs touted by celebrities and on TikTok to pare pounds — an even more powerful obesity medicine is poised to upend treatment.
Read more »
Medicare coverage could change with weight loss medication OzempicInsider tells the global tech, finance, markets, media, healthcare, and strategy stories you want to know.
Read more »
6 Ozempic facts that make sense of social media hypeSix weight loss drugs facts that you need to know, including how Ozempic works and common Ozempic side effects.
Read more »
Powerful new obesity drug poised to upend weight loss careA diabetes drug being tested for weight loss is poised to further upend obesity care
Read more »
Powerful new obesity drug poised to upend weight loss careA diabetes drug being tested for weight loss is poised to further upend obesity care. Drugmaker Eli Lilly and Co. reported Thursday that its drug tirzepatide helped people with diabetes who were overweight or had obesity lose up to 16% of their body weight over 17 months in a late-stage trial. For those without the disease, the drug has prompted losses of more than 20% of body weight. Known as Mounjaro for diabetes use, the drug has been used “off label” for weight loss since last year. Lilly is applying for fast-track approval from U.S. regulators and expects a decision this year. Analysts have predicted tirzepatide could become one of the top-selling drugs ever, with annual sales of more than $50 billion.
Read more »
Big Tech Companies Are Becoming More Powerful Than Nation-StatesThey are already richer than many countries, and the rise of AI looks set to increase their influence.
Read more »